{"id":"atazanavir-stavidine-lamivudine","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Hyperbilirubinemia (unconjugated)"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Headache"},{"rate":"15-20","effect":"Peripheral neuropathy (stavudine-related)"},{"rate":"variable","effect":"Lipodystrophy (stavudine-related)"},{"rate":"<1","effect":"Lactic acidosis (rare, stavudine-related)"}]},"_chembl":{"chemblId":"CHEMBL1200678","moleculeType":"Small molecule","molecularWeight":"802.95"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atazanavir is a protease inhibitor that prevents HIV protease from cleaving viral polyproteins, while stavudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that block the reverse transcriptase enzyme needed to convert HIV RNA into DNA. Together, these three agents target different steps of the HIV replication cycle to suppress viral load.","oneSentence":"This combination inhibits HIV replication by blocking reverse transcriptase and protease enzymes required for viral reproduction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:46.341Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"}]},"trialDetails":[{"nctId":"NCT00084253","phase":"PHASE4","title":"Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-06","conditions":"HIV Infections","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":269,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Reyataz"],"phase":"marketed","status":"active","brandName":"Atazanavir/ Stavidine / Lamivudine","genericName":"Atazanavir/ Stavidine / Lamivudine","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits HIV replication by blocking reverse transcriptase and protease enzymes required for viral reproduction. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}